We are monitoring the impact of COVID-19 on North America Nuclear Imaging Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1544
Share on
Share on

North America Nuclear Imaging Market Research Report – Segmented By Diagnostic Technologies, Application, Country (The United States, Canada and Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1544
Pages: 137

North America Nuclear Imaging Market Size (2021 to 2026)

The size of the Nuclear Imaging Market in North America is predicted to value USD 5.26 billion by 2026 and USD 3.48 billion in 2021, growing at a CAGR of 8.64% during the forecast period.

The nuclear imaging market in North American is primarily driven by the rising awareness of the benefits of nuclear imaging among clinical researchers and clinicians, as well as an increase in the number of applications such as cancer and neurology, an increase in the geriatric population, as well as the discovery and development of novel radiotracers. One of the primary factors driving the growth of this market is the increase in the number of cases of illness and diseases such as cardiovascular disease, cancer, and neurological disorder. Precise and high-quality images digitally generated after radiation are given to the patient to provide organ-specific diagnoses that lead to disease treatment. Thus, nuclear medicine has a lot of potential for treating cancer and heart disease. In addition, there is substantial evidence that using nuclear imaging methods to diagnose a tumor has a more significant influence on patient care regarding tumor surveillance and medication response.

Technological developments, growing diagnostic applications in different diseases such as cancer and cardiovascular diseases, government support, and the move from standalone to hybrid modalities drive the market forward in North America. Image processing and reconstruction, computer-assisted medical condition detection, 3D image creation, and the employment of suitable quality control systems are all possible with data integrated imaging systems. In addition, physicians may quickly compare scans with data integration to efficiently monitor disease progression. Aside from data integration, there is a significant opportunity to make data available via mobile technology. This will allow clinicians to examine and analyze scans from any location.

The high cost of diagnostic and treatment equipment and procedures has slowed the North American medical imaging market expansion. The main challenges for the North America Nuclear imaging market include increased research and development costs and highly advanced hybrid nuclear imaging equipment. Imaging technology developments have always been a challenge to practitioners regarding using them inpatient care effectively. In addition, radiopharmaceuticals' short half-life limits their potential adoption, while hospital budget cuts and costly equipment expenses are likely to hinder market growth to some extent.

This research report on the North American nuclear imaging market has been segmented & sub-segmented into the following categories:

By Product: 

  • Standalone PET Nuclear Imaging
  • Standalone SPECT Nuclear Imaging
  • Hybrid Nuclear Imaging

By Application: 

  • Oncology
  • Cardiology
  • Neurology
  • Others

By End-User: 

  • Hospitals
  • Diagnostic Centers
  • Research Centers

By Country: 

  • The United States
  • Canada
  • Rest of North America

Regionally, the large share and high growth in the U.S. can be credited to various factors such as authorization of new radiopharmaceuticals by the FDA and increasing focus on therapeutic nuclear medicine as a substitute treatment in oncology. With the largest market share, North America dominates the global market during the forecast period. Hybrid nuclear imaging, the development of molecular imaging, and novel radiotracer launches for diagnostics are all propelling the industry forward in the area. Tc99m (technetium 99) is a radioisotope widely used in nuclear medicine scans to image the body. One of the significant manufacturers of Technetium-99m in Canada. Tc-99m usage in radiopharmaceuticals is projected to propel the market in Canada to greater levels. It may also be combined with several biologically active compounds to provide non-invasive, real-time imaging of the human body. The United States held the highest proportion of the nuclear medicine market in 2020. The country's high ratio may be ascribed to new radioisotope manufacturing methods, government financing, and corporate activities. Due to factors such as the Centers for Medicare & Medicaid Services (CMS) expanding coverage for PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) imaging, rising usage of the systems in the early detection of Alzheimer's and cancer, improved healthcare reforms such as the Affordable Care Act, expanding health insurance. With an increase in healthcare expenditure, the United States is the largest market for nuclear imaging.

KEY MARKET PLAYERS:

Notable companies dominating the North American Nuclear Imaging market are Mallinckrodt plc, Siemens Medical Solutions, Hitachi Medical Corporation, Medtronic Inc., General Electric Co. (healthcare division), IBA Group, Positron Corporation, Philips Medical Systems, Naviscan, Toshiba Medical Systems Corporation, Carestream Health, Lantheus Medical Imaging Inc., Cardinal Health Inc., and Bayer AG. In addition, companies show a strong interest in enhancing image quality by developing new technologies and creating new devices or novel techniques to achieve images with higher spatial resolution.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Diagnostic Technologies                        

                                5.1.1 Introduction           

                                5.1.2 PET Radioisotopes

                                                5.1.2.1 Rubidium-82

                                                5.1.2.2 Fluorine-18

                                                5.1.2.3 Others

                                5.1.3 SPECT Radioisotopes          

                                                5.1.3.1 Thallium-201

                                                5.1.3.2 Technetium-99m

                                                5.1.3.3 Xenon-133

                                                5.1.3.4 Iodine-123

                                                5.1.3.5 Others

                                5.1.4 Y-o-Y Growth Analysis, By Diagnostic Technologies                

                                5.1.5 Market Attractiveness Analysis, By Diagnostic Technologies              

                                5.1.6 Market Share Analysis, By Diagnostic Technologies               

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 PET             

                                                5.2.2.1 Cardiology

                                                5.2.2.2 Oncology

                                                5.2.2.3 Neurology

                                                5.2.2.4 Others

                                5.2.3 SPECT        

                                                5.2.3.1 Lymphoma

                                                5.2.3.2 Neurology

                                                5.2.3.3 Cardiology

                                                5.2.3.4 Thyroid

                                                5.2.3.5 Others

                                5.2.4 Y-o-Y Growth Analysis, By Application         

                                5.2.5 Market Attractiveness Analysis, By Application        

                                5.2.6 Market Share Analysis, By Application         

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Diagnostic Technologies

                                                6.1.3.3 By Application

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Diagnostic Technologies

                                                6.1.4.3 By Application

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Diagnostic Technologies

                                                6.1.5.3 By Application

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Mallinckrodt plc                        

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Siemens Medical Solutions                  

                8.3 Hitachi Medical Corporation               

                8.4 Medtronic Inc.                          

                8.5 General Electric Co. (healthcare division)                       

                8.6 IBA Group                   

                8.7 Positron Corporation                              

                8.8 Philips Medical Systems                        

                8.9 Naviscan                      

                8.10 Toshiba Medical Systems Corporation                          

                8.11 Carestream Health                

                8.12 Lantheus Medical Imaging Inc.                         

                8.13 Cardinal Health Inc.                              

                8.14 Bayer AG                  

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Nuclear Imaging Market, By Region, From 2021 to 2026 (USD Billion)
  2. North America Nuclear Imaging Market, By Diagnostic Technologies , From 2021 to 2026 (USD Billion)
  3. North America PET Radioisotopes Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  5. North America Rubidium-82 Market, By Region, From 2021 to 2026 (USD Billion)
  6. North America Fluorine-18 Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Other PET radioisotopes Market, By Region, From 2021 to 2026 (USD Billion)
  8. North America SPECT Radioisotopes Market, By Region, From 2021 to 2026 (USD Billion)
  9. North America Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  10. North America Thallium-201 Market, By Region, From 2021 to 2026 (USD Billion)
  11. North America Technetium-99m Market, By Region, From 2021 to 2026 (USD Billion)
  12. North America Xenon-133 Market, By Region, From 2021 to 2026 (USD Billion)
  13. North America Iodine-123 Market, By Region, From 2021 to 2026 (USD Billion)
  14. North America Other SPECT radioisotopes Market, By Region, From 2021 to 2026 (USD Billion)
  15. North America Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  16. North America PET Market, By Region, From 2021 to 2026 (USD Billion)
  17. North America Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  18. North America Cardiology Market, By Region, From 2021 to 2026 (USD Billion)
  19. North America Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  20. North America Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  21. North America Other PET applications Market, By Region, From 2021 to 2026 (USD Billion)
  22. North America SPECT Market, By Region, From 2021 to 2026 (USD Billion)
  23. North America Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)
  24. North America Lymphoma Market, By Region, From 2021 to 2026 (USD Billion)
  25. North America Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  26. North America Cardiology Market, By Region, From 2021 to 2026 (USD Billion)
  27. North America Thyroid Market, By Region, From 2021 to 2026 (USD Billion)
  28. North America Other SPECT applications Market, By Region, From 2021 to 2026 (USD Billion)
  29. United States Nuclear Imaging Market, By Diagnostic Technologies , From 2021 to 2026 (USD Billion)
  30. United States Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  31. United States Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  32. United States Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  33. United States Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  34. United States Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)
  35. Canada Nuclear Imaging Market, By Diagnostic Technologies, From 2021 to 2026 (USD Billion)
  36. Canada Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  37. Canada Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  38. Canada Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  39. Canada Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  40. Canada Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample